Login to Your Account



BIOSIMILAR PATH AT RISK

India high court bans promotion of Roche’s Herceptin biosimilars by Biocon, Mylan

By Cornelia Zou
Staff Writer

Wednesday, February 12, 2014

HONG KONG – The High Court of Delhi has forbidden Biocon Ltd. and Mylan Inc. from comparing Canmab and Hertraz to Roche AG’s breast cancer drug Herceptin (trastuzumab), even though they were approved as biosimilar versions of the drug.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription